论文部分内容阅读
用过继免疫疗法(adoptive immunothe-raPy)治疗肿瘤已有相当长的历史,但由于不能获得足够量的抗肿瘤活性细胞,使此疗法没有得到广泛的应用。自从 IL-2被发现后,人们能够在体外对淋巴细胞进行长期培养和大量扩增~(1),从而克服了过继免疫疗法中所需要效应细胞数量不足的困难。Grimm等(1982)~(2)用淋巴细胞在含IL-2培养基中培育的方法获得了一种能杀伤抵抗NK活性的肿瘤细胞的新型杀伤细胞,定名
The use of adoptive immunotherapies to treat tumors has a long history but therapies have not been widely used because of the inability to obtain sufficient quantities of antitumor activity. Since the discovery of IL-2, one can long-term culture and extensively expand lymphocytes in vitro ~ (1), thus overcoming the difficulties of insufficient number of effector cells in adoptive immunotherapy. Grimm et al. (1982) ~ (2) obtained a new type of killer cell that can kill tumor cells resistant to NK activity by means of culturing lymphocytes in IL-2 containing medium.